Binita Palaria

Binita Palaria

Auto-generated profile, based on publicly available information

Binita Palaria

Department of Pharmacy, Devsthali Vidyapeeth College of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Abhishek TiwariAbhishek Tiwari
Abhishek Tiwari
VTVarsha Tiwari
Varsha Tiwari
BPBinita Palaria
Binita Palaria
MKManish Kumar
Manish Kumar
DKDeepak Kaushik
Deepak Kaushik
Background: A microsponge delivery system (MDS) is an innovative and unique way of delivering drugs in a structured manner. Using microsponge drug delivery, regulated drug delivery may now be achieved quickly and easily. Main body: MDS comprises porous microspheres ranging in size from 5 to 300 microns, with a large porous structure and a very tiny spherical shape. MDS is normally used to deliver drugs via topical channels, but they have recently shown the potential approach to drug delivery via oral, ophthalmic and parenteral routes. MDS can easily modify the pharmaceutical release contour and improve formulation stability while minimising the negative impact of the drug. The fundamental purpose of microsponge drug administration is to reach the highest possible peak plasma concentration in the blood. The capacity of MDS to self-sterilise is their most prominent attribute. Conclusions: MDS is used as anti-allergic, anti-mutagenic and non-irritant in innumerable investigations. This review includes formulation, criteria for drugs to be incorporated in MDS, formulation methods, assessment parameters, and role of MDS in the management of various disorders. This review will be quite useful in the future in exploring the MDS in different disorders. Graphical

1 April 2023 in Current Nanomaterials
Verified
Journal Article
Closed access
PDF file
Abhishek TiwariAbhishek Tiwari
Abhishek Tiwari
BPBinita Palaria
Binita Palaria
VTVarsha Tiwari
Varsha Tiwari
RARamsha Aslam
Ramsha Aslam
AKAshok Kumar
Ashok Kumar
SKSuresh Kumar
Suresh Kumar
Nanostructured lipid carriers (NLCs) are considered second-generation lipid-based pharmaceutical formulations in drug delivery systems. It is a more efficient drug delivery system that includes the development of a nano-particulate system, and it is superior to the conventional drug delivery system. Among all available nanoparticles, NLC has gained more attention due to its superior characteristics, such as being lipophilic, biodegradable, and biocompatible. This lipid nanoparticulate system is more advantageous over liposomes, microparticles, emulsions, and solid lipid nanoparticles. NLCs have emerged as a promising carrier for the delivery of targeted drug substances via oral, parenteral, topical, pulmonary, transdermal, and ocular routes. These nanocarriers are utilized for the delivery of both lipophilic as well as hydrophilic drugs. NLCs are composed of a matrix of physiological lipids, i.e., solid lipid and liquid lipid, emulsifiers, and water. NLCs provide an opportunity for large-scale production, ease of preparation with enhanced encapsulation, targeted efficiency, and reduced toxic effects. This review is focused on the advantages, limitations, methods of preparation, characterization, and applications of NLCs.

21 November 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
Abhishek TiwariAbhishek Tiwari
Abhishek Tiwari
VTVarsha Tiwari
Varsha Tiwari
BPBinita Palaria
Binita Palaria
RARamsha Aslam
Ramsha Aslam
MKManish Kumar
Manish Kumar
NKNeeraj Kumar
Neeraj Kumar
Fungal infections (FIs) affect majority of the population, but the current treatments face challenges in terms of their effectiveness. This study focused on specific fungal targets, including dihydrofolate reductase (DHFR), acetohydroxy-acid synthase (AHAS), farnesyltransferase and endoglucanase. The docking studies were conducted with the drug voriconazole (VCZ), comparing it with Fluconazole (FCZ) and Amphotericin B (ATB) against 11 protein data bank (PDB) IDs (IDYR, 3NZB, 6DEQ, 1KS5, 7T0C, 1FY4, 5AJH, 7R79, 6TZ6 and 6IDY). Molecular dynamics (MD) analysis, including RMSD, RMSF, PCA and FEL, confirmed the stability of VCZ. The solubility of VCZ was a problem, so nanostructured lipid carriers (NLCs) were developed to improve ocular penetration. VCF5 was the optimized formulation by using 32 full factorial design. VCZF5-NLCs were the best in terms of nanoparticle size (126.6 nm), Zeta potential (33.5 mV), drug content (DC; 97.38 ± 0.210), encapsulation efficiency (EE; 88.01 ± 0.272) and extended drug release. The results of the ex-vivo corneal diffusion study indicate that VCZ-NLC-loaded in-situ gel (VCZ-NLC-IG3) exhibited DC of 88.25% and drug entrapment (DE) of 74.2%. The results of the zone of inhibition indicated that VCZ-NLC-IG3 had superior efficacy compared to ATB. Network pharmacology showed VCZ interacts with the genes which are responsible for fungus ergosterol biosynthesis, including lanosterol 14-alpha demethylase inhibitors (ERG11), ergosterol biosynthesis protein 5 (ERG5), dimethylallyltransferase 2 (DIT2), ketosynthase (KCN), methylsterol monooxygenase (MSMO1), lamin B receptor (LBR), squalene epoxidase (SQLE), 3-hydroxy-3-methylglutaryl-coenzyme A Reductase (MGCR), 3-hydroxy-3-methylglutaryl-coenzyme A Synthase (HMGCS) and 3-keto-steroid reductase (HSD17B7). In conclusion, the optimized VCZ-loaded NLCs present a promising approach to treat ocular FIs.Communicated by Ramaswamy H. Sarma.